Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | CCKBR | P32239 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL300194 | 0.90 | BACE1 (0.39) | BACE1HCRTR1HCRTR2BACE2CCKBR | |
| SCHEMBL297609 | 0.86 | MAPT (0.44) | BACE1HCRTR1HCRTR2CCKBR | |
| SCHEMBL286692 | 0.80 | BACE1 (0.43) | BACE1HCRTR1HCRTR2BACE2CCKBR | |
| SCHEMBL286691 | 0.80 | BACE1 (0.43) | BACE1HCRTR1HCRTR2BACE2CCKBR | |
| SCHEMBL299154 | 0.79 | BACE1 (0.47) | BACE1HCRTR1HCRTR2BACE2 | |
| SCHEMBL299155 | 0.79 | BACE1 (0.47) | BACE1HCRTR1HCRTR2BACE2 | |
| SCHEMBL297672 | 0.76 | MAPT (0.42) | BACE1CCKBR | |
| SCHEMBL2884694 | 0.76 | BACE1 (0.41) | BACE1BACE2PRMT5WDR77 | |
| SCHEMBL287446 | 0.75 | BACE1 (0.41) | BACE1HCRTR1HCRTR2BACE2 | |
| SCHEMBL287445 | 0.75 | BACE1 (0.41) | BACE1HCRTR1HCRTR2BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461160-B2 | Dihydropyrimidinones | HOFFMANN-LA ROCHE, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | BACE2, BACE1, PSEN2 | BACE1 2/4885HCRTR1 807/4885HCRTR2 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.